Long term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely the result of laboratory abnormalities

Annals of the Rheumatic Diseases

Volumn 64, Issue 2, 2005, Pages 207-211

  Yazici, Yusuf ^a,b   Sokka, T ^c,d   Kautiainen, H ^e   Swearingen, C ^c   Kulman, I ^f   Pincus, T ^c  

^a Long Island College Hospital ^*  (United States)

^b LONG ISLAND COLLEGE HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^e RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MOUTH ULCER; PNEUMONIA; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SKIN NODULE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; LIVER DISEASES; MALE; METHOTREXATE; MIDDLE AGED; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 13244295795     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.023408     Document Type: Article

References (28)

1. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;29:2521-4.
2. Hanrahan PS, Scrivens GA, Russell AS. Prospective long term followup of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 1989;28:147-53.
3. Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures JP. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J Rheumatol 1991;18:1323-7.
4. Mielants H, Veys EM, Van Der Straeten C, Ackerman C, Goemaere S. The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: An open prospective study. J Rheumatol 1991;18:978-83.
5. Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995;54:708-12.
6. Rau R, Schleusser B, Herborn G, Karger T. Longterm treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997;24:1881-9.
7. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;43:14-21.
8. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
9. Pincus T, Marcum SB, Callahan LF, Adams RF, Barber J, Barth WF, et al. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. I. Nonsteroidal anti-inflammatory drugs. J Rheumatol 1992;19:1874-84.
10. Yazici Y, Erkan D, Paget SA. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines? J Rheumatol 2002;29:1580-9.
11. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994;121:833-41.
12. Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum 2003;48:2769-72.
13. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolf VA. Temporary remission in acute leukemia in children produced by folic acid antagonist 4-amethopteroylglutamicacid (aminopterin). N Engl J Med 1948:787-93.
14. Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
17. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second-line drugs and prednisone. J Rheumatol 1992;19:1885-94.
18. Physicians' Desk Reference. Montvale, NJ: Thomson PDR 2003.
19. Bridges SL, Alarcon GS, Koopman WJ. Methotrexate-induced liver abnormalities in rheumatoid arthritis. J Rheumatol 1989;16:1180-3.
20. Shergy WJ, Polisson RP, Caldwell DS, Rice JR, Pisetsky DS, Allen NB. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988;85:771-4.
21. Rau R, Karger T, Herborn G, Frenzel H. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J Rheumatol 1989;16:489-93.
22. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989;32:121-7.
23. Bergquist SR, Felson DT, Prashker MJ, Freedberg KA. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1995;38:326-33.
24. Zachariae H, Sogaard H. Methotrexate-induced liver cirrhosis: a follow-up. Dermatologica 1987;75:178-82.
25. Cartwright VW, Michaud K, Choi HK, Wolfe F. Methotrexate, laboratory testing and risk of serious illness: analyses in 20 000 patients. Arthritis Rheum 2003;48:S428.
26. Pincus T, Callahan LF. The "side effects" of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 1993;32(suppl. 1):28-37.
27. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26-34.
28. Kremer JM, Alarcon GS, Lightfoot RW, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.